Intravitreal bevacizumab in pigmented rabbit eyes: Histological analysis 90 days after injection;Bevacizumabe intravítreo em olhos de coelhos não albinos: Análise histológica 90 dias após a injeção

Arquivos Brasileiros de Oftalmologia

Volumn 72, Issue 5, 2009, Pages 655-660

  Arraes, João Carlos Diniz ^a   Tedesco, Roberto Carlos ^b   Arraes, Tatiana Azevedo ^c   da Silva, Elilson Batista ^d   Ventura, Alexandre ^c   de Ávila, Marcos Pereira ^c  

^a UNIVERSIDADE FEDERAL DO TOCANTINS   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

^d Médico Veterinário   (Brazil)

Author keywords

Angiogenesis inhibitors; Injections; Macula lutea; Macular degeneration; Models, animal; Neovascularization, pathologic; Rabbits; Retina drug effects

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; MONOCLONAL ANTIBODY;

ANIMAL; ANIMAL MODEL; ARTICLE; DRUG EFFECT; FEMALE; MALE; PATHOLOGY; PIGMENT EPITHELIUM; RABBIT; RETINA;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; FEMALE; MALE; MODELS, ANIMAL; RABBITS; RETINA; RETINAL PIGMENT EPITHELIUM;

EID: 74049141342     PISSN: 00042749     EISSN: 16782925     Source Type: Journal    
DOI: 10.1590/s0004-27492009000500011     Document Type: Article

References (23)

1. Gragoudas ES, Adamis AP, Cunningham ET Jr., Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351(27): 2805-16.2805-16. Comment in: ACP J Club. 2005;143(1):18. N Engl J Med. 2004; 351(27):2863-5. N Engl J Med. 2005;352(16):1720-1; author reply 1720-1.
2. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-31. Comment in: N Engl J Med. 2006;355(14):1409-12. N Engl J Med. 2006;355(14):1493-5. N Engl J Med. 2007;356(7):747-8; author reply 749-50. N Engl J Med. 2007;356(7):748-9; author reply 749-50.
3. Colquitt JL, Jones J, Tan SC, Takeda A, Clegg AJ, Price A. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation. Health Technol Assess. 2008;12(16):iii-iv, ix-201.
4. Azad R, Chandra P, Gupta R. The economic implications of the use of antivascular endothelial growth factor drugs in age-related macular degeneration. Indian J Ophthalmol. 2007;55(6):441-3.
5. Brasil. Ministério da Saúde. Agencia Nacional de Vigilância Sanitária. Inibidores da angiogênese para o tratamento da degeneração macular relacionada à idade. Bol Bras Aval Tecnol Saúde. 2008[citado 2009 Jan 12];3(6). Disponível em: http://www.anvisa.gov.br/divulga/newsletter/brats/2008/brats6.pdf
6. Kerr DJ. Targeting angiogenesis in cancer: clinical development of bevacizumab. Nat Clin Pract Oncol. 2004;1(1):39-43.
7. Ellis LM. Bevacizumab. Nat Rev Drug Discov. 2005;(Suppl):S8-9. Review.
8. Ma J, Waxman DJ. Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol Cancer Ther. 2008;7(12):3670-84.
9. Ip MS, Scott IU, Brown GC, Ho AC, Huang SS, Recchia FM; American Academy of Ophthalmology. Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology. Ophthalmology. 2008;115(10):1837-46.
10. Raftery J, Clegg A, Jones J, Tan SC, Lotery A. Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness. Br J Ophthalmol. 2007; 91(9):1244-6. Comment in: Br J Ophthalmol. 2008;92(7):1010. Br J Ophthalmol. 2008;92(6):866-7.
11. Bashshur ZF, Haddad ZA, Schakal A, Jaafar RF, Saab M, Noureddin BN. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Am J Ophthalmol. 2008;145(2):249-56.Comment in: Am J Ophtalmol. 2008;145(5):937; author reply 938.
12. Dib E, Maia M, Longo-Maugeri IM, Martins MC, Mussalem JS, Squaiella CC, et al. Subretinal bevacizumab detection after intravitreous injection in rabbits. Invest Ophthalmol Vis Sci. 2008;49(3):1097-100.
13. Spitzer MS, Wallenfels-Thilo B, Sierra A, Youeruek E, Peters S, Henke-Fahie S, Bartz-Schmidt KU, Szurman P; Tuebingen Bevacizumab Study Group. Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells. Br J Ophthalmol. 2006;90(10):1316-21.
14. Kernt M, Welge-Lüssen U, Yu A, Neubauer AS, Kampik A. [Bevacizumab is not toxic to human anterior- and posterior-segment cultured cells]. Ophthalmologe. 2007;104(11):965-71. German.
15. Maia M, Margalit E, Lakhanpal R, Tso MO, Greve R, Torres G, et al. Effects of intravitreal indocyanine green injection in rabbits. Retina. 2004;24(1):69-79.
16. Komarowska I, Heilweil G, Rosenfeld PJ, Perlman I, Loewenstein A. Retinal toxicity of commercially available intravitreal ketorolac in albino rabbits. Retina. 2009;29(1):98-105.
17. Smith RS, Jonh SWM, Nishina PM. Smith RS, Sundberg JP, editors. Systematic evaluation of the mouse eye: anatomy, pathology and biomethods. Danvers, MA: CRC Press; 2000. Retina, p.195-225.
18. Feiner L, Barr EE, Shui YB, Holekamp NM, Brantley MA Jr. Safety of intravitreal injection of bevacizumab in rabbit eyes. Retina. 2006;26(8):882-8.
19. Inan UU, Avci B, Kusbeci T, Kaderli B, Avci R, Temel SG. Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes. Invest Ophthalmol Vis Sci. 2007;48(4): 1773-81.
20. Manzano RP, Peyman GA, Khan P, Kivilcim M. Testing intravitreal toxicity of bevacizumab (Avastin). Retina. 2006;26(3):257-61.
21. Shahar J, Avery RL, Heilweil G, Barak A, Zemel E, Lewis GP, et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina. 2006;26(3):262-9.
22. Ameri H, Chader GJ, Kim JG, Sadda SR, Rao NA, Humayun MS. The effects of intravitreous bevacizumab on retinal neovascular membrane and normal capillaries in rabbits. Invest Ophthalmol Vis Sci. 2007;48(12):5708-15.
23. Bakri SJ, Cameron JD, McCannel CA, Pulido JS, Marler RJ. Absence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model. Am J Ophthalmol. 2006;142(1):162-4.